Search
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Pegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigationalPegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in ...
DiaPep 277
go.drugbank.com/drugs/DB06651InvestigationalDiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).
Bexicaserin
go.drugbank.com/drugs/DB18885InvestigationalBexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).
Fosigotifator
go.drugbank.com/drugs/DB19409InvestigationalFosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).
Sulindac
go.drugbank.com/drugs/DB00605ApprovedInvestigationalSulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril.
ING-1
go.drugbank.com/drugs/DB05831InvestigationalING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most
Human thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalThis transformation mimics the final coagulation cascade step which involves the clotting mass that adheres to the wound surface and achieves hemostasis and sealing of open tissues.
Elgemtumab
go.drugbank.com/drugs/DB15430InvestigationalElgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer